What is the recommended approach to managing polypharmacy in patients?

Managing Polypharmacy: A Systematic Approach

Implement a structured, stepwise medication review process beginning with complete medication reconciliation, followed by systematic identification of drug therapy problems, prioritized deprescribing of high-risk medications using Beers or STOPP/START criteria, and alignment with patient-specific goals of care. 1

Core Framework: The 9-Step Systematic Review

The most recent and comprehensive guidelines 1 establish a clear algorithmic approach to polypharmacy management:

Step 1: Medication Reconciliation

• Document every medication the patient actually takes (not just what's prescribed)
• Include over-the-counter drugs, supplements, and herbals
• Identify discontinued medications still being taken, unfilled prescriptions, and medications taken incorrectly
• This is a Joint Commission safety priority and reduces medication errors at care transitions 1

Step 2: Adherence Assessment

• Use validated tools like the Morisky Medication Adherence Scale 1
• Review pill boxes, bottles, and fill dates directly
• Identify barriers: complex dosing schedules (3-4 times daily), cost issues, side effects
• Action: Simplify regimens to once or twice daily dosing whenever possible

Step 3: Drug-Drug Interaction Screening

• Use interaction databases to identify high-risk combinations
• Prioritize: QT prolongation risks, anticoagulant interactions, serotonin syndrome potential
• Action: Select non-interacting alternatives or eliminate when risk exceeds benefit 1

Step 4: Drug-Disease Interaction Review

• Screen for contraindications: NSAIDs in heart failure/CKD, sulfonylureas in renal impairment
• Action: Switch to safer alternatives immediately 1

Step 5: Identify Duplicate/Overlapping Therapy

• Look for medications with additive side effects or duplicate mechanisms
• Action: Taper and consolidate therapy 1

Step 6: Apply High-Risk Medication Criteria

Use Beers Criteria or STOPP/START tools to identify potentially inappropriate medications 1:

• Sedative-hypnotics, benzodiazepines, opioids
• Anticholinergics (diphenhydramine, cyclobenzaprine, oxybutynin)
• Hypoglycemics (especially sulfonylureas and short-acting insulin)
• These medications cause falls, delirium, cognitive decline, and emergency department visits 1

Step 7: Screen for Undertreated Conditions

• Use START criteria to identify missing evidence-based therapies
• Example: CAD without statin, post-stenting without antiplatelet
• Action: Initiate beneficial medications within patient's goals of care 1

Step 8: Monitor for Efficacy and Safety

• Verify appropriate laboratory monitoring (TSH, INR, glucose, renal function)
• Adjust doses for declining kidney clearance (antibiotics, digoxin, anticoagulants, hypoglycemics) 1
• Critical: Aging reduces drug clearance and increases sensitivity to medications 1

Step 9: Eliminate Non-Essential Supplements

• Most multivitamins and supplements are non-contributive except vitamin D
• These add cost, burden, and interaction risk 1

Patient-Centered Decision Making

All medication changes must align with patient preferences, life expectancy, and goals of care 2:

• Use shared decision-making for all changes
• Consider time-to-benefit: statins and bisphosphonates only benefit patients with >5 years estimated survival 2
• Prioritize quality of life over disease-specific targets in frail elderly
• Relax glycemic targets and avoid hypoglycemia-inducing agents in older adults 1

Team-Based Implementation

Involve clinical pharmacists in medication reviews—they reduce potentially inappropriate medications by 36.4% 1. The team should include:

• Pharmacist for medication assessment and drug therapy problem identification
• Physician for prescribing authority and care coordination
• Nurse for adherence support and monitoring
• Patient and caregivers for shared decision-making

Deprescribing Protocol

When stopping medications, follow this systematic approach 2, 3:

1. Prioritize medications with lowest benefit-harm ratio
2. Stop one medication at a time (not multiple simultaneously)
3. Consider tapering rather than abrupt discontinuation for medications with withdrawal risk
4. Monitor closely for improvement or adverse withdrawal effects
5. Communicate the plan clearly with patient and all prescribers

Specific High-Risk Deprescribing Targets

Anticholinergics: These cause vision problems, urinary retention, constipation, and cognitive decline—switch to alternatives immediately 1

Hypoglycemics: Deintensify when hypoglycemia occurs; sulfonylureas and short-acting insulin are highest risk 1

Proton pump inhibitors: Often unnecessary long-term; target for discontinuation 1

Critical Pitfalls to Avoid

• Don't rely on medication lists alone—patients often take different medications than documented 1
• Don't ignore supplements and OTC medications—they contribute to interactions and burden 1
• Don't apply single-disease guidelines to multimorbid patients—evidence from younger, healthier populations overestimates benefits and underestimates harms 2
• Don't forget care transitions—medication errors spike during hospital-to-home transitions 1
• Don't deprescribe without patient agreement—education about risks and collaborative decision-making are essential 1

Coordination and Follow-Up

• Select a primary pharmacy to coordinate all prescriptions and identify duplicates 2
• Designate a care coordinator for complex patients, especially during transitions 2
• Schedule follow-up within 2-4 weeks after medication changes to monitor outcomes 4
• Document all changes in a shared care plan accessible to all providers 2

Outcomes That Matter

This systematic approach reduces 1:

• Drug-related hospitalizations and emergency visits
• Falls with injury
• Delirium episodes
• Healthcare costs
• Medication non-adherence

The goal is optimizing benefit over harm while enhancing quality of life and reducing treatment burden 2, 1.